mRNA COVID Vaccines Reduce Severity Of Delta, Omicron. Deets Here

New Delhi: A new study has found that those who have received the mRNA Covid vaccine are less likely to suffer severe illness from the coronavirus infection. According to the study, people who received two or three doses of the mRNA Covid-19 vaccine were significantly more likely to develop mild illness when infected with the delta or omicron coronavirus variants than unvaccinated people.Also Read – Covid mRNA vaccines increase risk of cardiac-related death in men aged 18-39, here’s how to take care of your heart – see

The study, published in the Journal of the American Medical Association (JAMA), was conducted by a team of researchers from the University of Utah. For the research, health care workers, first responders and other frontline workers were screened in the US, news agency IANS reported that “we know that there are more cases of progression with Delta and Omicron than with the initial strain, but Vaccines still work well. to limit the severity of infection,” Sarang Yun, assistant professor in the Department of Family and Preventive Medicine at University of Utah Health, said in the published study.

How the study was conducted

For the study, researchers examined 1,199 participants who developed a Covid-19 infection. Of the participants, 24 percent were infected with Delta and 62 percent were infected with Omicron, while 14 percent had the original virus strain.

In the case of Delta, participants who received two doses of the vaccine were significantly less likely to have symptoms than those who were not vaccinated.

In the case of Omicron, the risk of symptomatic infection was similar between participants who received two doses of the vaccine and those who did not receive the vaccine, while those who received three doses experienced a higher risk than those who were not vaccinated.

The authors noted that, while the study is the largest of its kind testing Covid-19 vaccines over time and across different types, the differences and grouping of participants by vaccine status resulted in some combinations with relatively few people, affecting the accuracy of the findings. There were also results that were characterized as “unexpected” in participants who received three doses and had symptomatic Omicron infections.